Multiparametric magnetic resonance imaging in the assessment of anti-EGFRvIII chimeric antigen receptor T cell therapy in patients with recurrent glioblastoma

• Published in: British journal of cancer Vol. 120; no. 1; pp. 54 - 56
• Main Authors: Wang, Sumei, O’Rourke, Donald M., Chawla, Sanjeev, Verma, Gaurav, Nasrallah, MacLean P., Morrissette, Jennifer J. D., Plesa, Gabriela, June, Carl H., Brem, Steven, Maloney, Eileen, Desai, Arati, Wolf, Ronald L., Poptani, Harish, Mohan, Suyash
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 08.01.2019; Nature Publishing Group
• Subjects: 692/4028; 692/4028/67/2321; Antigens; Biomedical and Life Sciences; Biomedicine; Brain cancer; Brief Communication; Cancer Research; Cell Line, Tumor; Chimeric antigen receptors; Drug Resistance; Epidemiology; ErbB Receptors - antagonists & inhibitors; ErbB Receptors - immunology; Female; Glioblastoma; Glioblastoma - diagnostic imaging; Glioblastoma - immunology; Glioblastoma - pathology; Glioblastoma - therapy; Humans; Immunotherapy, Adoptive; Lymphocytes T; Magnetic Resonance Imaging; Male; Middle Aged; Molecular Medicine; Neoplasm Recurrence, Local - diagnostic imaging; Neoplasm Recurrence, Local - immunology; Neoplasm Recurrence, Local - pathology; Neoplasm Recurrence, Local - therapy; NMR; Nuclear magnetic resonance; Oncology; Patients; Receptors, Chimeric Antigen - immunology; Receptors, Chimeric Antigen - therapeutic use; Surgery
• ISSN: 0007-0920; 1532-1827; 1532-1827
• DOI: 10.1038/s41416-018-0342-0

EGFRvIII targeted chimeric antigen receptor T (CAR-T) cell therapy has recently been reported for treating glioblastomas (GBMs); however, physiology-based MRI parameters have not been evaluated in this setting. Ten patients underwent multiparametric MRI at baseline, 1, 2 and 3 months after CAR-T therapy. Logistic regression model derived progression probabilities (PP) using imaging parameters were used to assess treatment response. Four lesions from “early surgery” group demonstrated high PP at baseline suggestive of progression, which was confirmed histologically. Out of eight lesions from remaining six patients, three lesions with low PP at baseline remained stable. Two lesions with high PP at baseline were associated with large decreases in PP reflecting treatment response, whereas other two lesions with high PP at baseline continued to demonstrate progression. One patient didn’t have baseline data but demonstrated progression on follow-up. Our findings indicate that multiparametric MRI may be helpful in monitoring CAR-T related early therapeutic changes in GBM patients.